Showing 2011-2020 of 5771 results for "".
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- Zhaoke Ophthalmology Announces First Patient Completes 3-Year Enrollment in Phase 3 Myopia Trialhttps://modernod.com/news/zhaoke-ophthalmology-announced-first-patient-completes-3-year-enrollment-in-phase-3-myopia-trial/2478533/Zhaoke Ophthalmology Pharmaceutical has announced that the first patient has completed 3-year enrollment in the phase 3 CHAMP (Childhood Atropine for Myopia Progression) study carried out by its partner, Nevakar. The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound
- Samsung Bioepis Announces 1-year Results From Phase 3 Study of SB11 Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-1-year-results-from-phase-3-study-of-sb11-proposed-lucentis-biosimilar/2478526/Samsung Bioepis announced 1-year results from the phase 3 study on SB11, a proposed biosimilar to Lucentis (ranibizumab), in patients with neovascular age-related macular degeneration (AMD). This data will be presented for the first time at the American Academy of Ophthalmology (AAO) 2020 Virtual
- Gyroscope Therapeutics Announces First Patient Dosed in Phase 2 Trial Evaluating Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-2-trial-evaluating-investigational-gene-therapy-for-dry-amd/2478523/Gyroscope Therapeutics announced the initiation of the phase 2 HORIZON trial evaluating GT005 in people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The first patient to receive GT005 in HORIZON was enrolled and dosed in the United States by Jeff
- Regenxbio Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meetinghttps://modernod.com/news/regenxbio-announces-presentations-at-the-american-academy-of-ophthalmology-2020-annual-meeting/2478516/Regenxbio announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format. The first presentation will feature data from the RGX-314 phase 1/2 subret
- New Alcon Innovations in IOLs, Digital Health Solutions to be Showcased at the AAO 2020 Virtual Annual Meetinghttps://modernod.com/news/new-alcon-innovations-in-iols-digital-health-solutions-to-be-showcased-at-the-aao-2020-virtual-annual-meeting/2478506/Alcon will highlight a robust scientific program including new data and advancements across its portfolio of innovations in cataract, refractive and retina surgery during the American Academy of Ophthalmology (AAO) 2020 virtual annual meeting, which takes place November 13-15, 2020, according to
- Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code From the AMA for the Insertion of Intracanalicular Insertshttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-a-permanent-category-i-cpt-code-from-the-ama-for-the-insertion-of-intracanalicular-inserts/2478492/Ocular Therapeutix announced that its application for the creation of a Category I Current Procedural Terminology (CPT) procedure code, presented at the October 2020 American Medical Association (AMA) CPT Editorial Panel meeting, has been granted. The Panel has accepted the addition of a permanen
- Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy for Dry AMD Via Orbit SDShttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-received-investigational-gene-therapy-for-dry-amd-via-orbit-subretinal-delivery-system/2478480/Gyroscope Therapeutics announced that the first surgery using its proprietary Orbit Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been condu
- Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement for Dextenza and OTX-TIC in Asiahttps://modernod.com/news/ocular-therapeutix-and-affamed-therapeutics-announce-license-agreement-and-collaboration-for-dextenza-and-otx-tic-in-asia/2478479/Ocular Therapeutix announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC in Greater China, South Korea, and the ASEAN markets. Dextenza is currently approved in the U.S. for the treatment of post-surgical ocul
- Norlase Announces FDA Clearance and US Launch of New LION Laser Systemhttps://modernod.com/news/norlase-announces-fda-clearance-and-u-s-launch-of-new-lion-laser-system/2478470/Norlase announced the 510(k) clearance from the FDA and the immediate commercial launch of Norlase LION, a green laser photocoagulator fully-integrated into a Keeler indirect ophthalmoscope. Unlike other laser indirect ophthalmoscopes that require a fiber optic connection to a laser source